Related Experiment Video
Updated: Sep 2, 2026

Inducing Meningococcal Meningitis Serogroup C in Mice via Intracisternal Delivery
Published on: November 5, 2019
Meningococcal Surveillance Australia: Reporting period 1 January to 31 March 2026
Monica Lahra1, Sandra He2, Tiffany Hogan3
1The World Health Organization Collaborating Centre for STI and AMR and Neisseria Reference Laboratory, NSW Health Pathology, Microbiology, Prince of Wales Hospital, Randwick, NSW 2031, Australia; School of Medical Sciences, Faculty of Medicine, University of New South Wales, Kensington, NSW 2052, Australia. monica.lahra@health.nsw.gov.au.
Abstract:
The reference laboratories of the Australian Meningococcal Surveillance Programme (AMSP) report data on the number of cases of invasive meningococcal disease (IMD) confirmed by laboratory testing using culture and molecular based techniques. Data contained in quarterly reports are restricted to a description of case numbers of IMD by jurisdiction and serogroup, where known and expanded in 2024 to include antimicrobial resistance data for ceftriaxone, penicillin, ciprofloxacin and rifampicin. A full analysis of laboratory confirmations of IMD in each calendar year are contained in the AMSP annual reports.
Related Concept Videos
Bacterial Meningitis I: Introduction
Viral Meningitis
Bacterial Meningitis
Bacterial Meningitis II: Pathophysiology
Cryptococcal Meningitis
Investigation of Disease Outbreaks
